What is Collegium Pharmaceutical?
Headquartered in Stoughton, Massachusetts, Collegium Pharmaceutical is a specialty pharmaceutical company dedicated to the development and commercialization of innovative medicines for pain management. The company's diverse portfolio addresses significant unmet needs in the market, featuring key products such as Xtampza ER, an abuse-deterrent formulation of oxycodone, and various formulations of tapentadol and buprenorphine. By focusing on extended-release and specialized delivery mechanisms, Collegium aims to improve patient outcomes while addressing the challenges associated with long-term opioid treatment and chronic pain management. The firm's market position is bolstered by its commitment to scientific rigor and its strategic focus on high-barrier-to-entry therapeutic areas.
How much funding has Collegium Pharmaceutical raised?
Collegium Pharmaceutical has raised a total of $1.1B across 12 funding rounds:
Debt
$1M
Series B
$22.5M
Private Equity
$4M
Other Financing Round
$50M
Stock Offering
$69.6M
Stock Offering
$55M
Stock Offering
$80M
Stock Offering
$125M
Debt
$650M
Debt (2010): $1M featuring Boston Millennia Partners
Series B (2012): $22.5M backed by Skyline Ventures, Frazier Healthcare Partners, Longitude Capital, and Boston Millennia Partners
Private Equity (2013): $4M, investors not publicly disclosed
Other Financing Round (2015): $50M led by Eventide Asset Management, Boston Millennia Partners, EcoR1 Capital, Longitude Capital, Skyline Ventures, APERTURE Venture Partners, Rock Springs Capital, Frazier Healthcare Partners, RA Capital Management, TPG Biotech, and Adage Capital Management
Stock Issuance/Offering (2015): $69.6M, investors not publicly disclosed
Stock Issuance/Offering (2016): $55M, investors not publicly disclosed
Stock Issuance/Offering (2016): $80M, investors not publicly disclosed
Stock Issuance/Offering (2020): $125M, investors not publicly disclosed
Debt (2022): $650M led by Pharmakon Advisors
Key Investors in Collegium Pharmaceutical
Boston Millennia Partners
Boston Millennia Partners provides private equity financing to high growth companies in the healthcare and life sciences industry, leveraging over one hundred years of combined experience to drive value.
Frazier Healthcare Partners
Frazier Healthcare Partners is a prominent investment firm focused on the biopharmaceutical sector, supporting companies through late clinical-stage development and commercialization.
Westfield Capital Management
Westfield Capital Management is an SEC-registered investment advisor that utilizes research-driven strategies to manage growth equity products for institutional and individual clients.
What's next for Collegium Pharmaceutical?
With the recent infusion of capital, Collegium Pharmaceutical is well-positioned to accelerate its strategic initiatives, including the potential expansion of its product pipeline and the optimization of its commercial infrastructure. The company's focus remains on leveraging its existing assets to drive sustainable growth while maintaining a rigorous commitment to patient safety and therapeutic efficacy. As the firm continues to evolve, the integration of new financing will likely support further research and development efforts, ensuring that Collegium remains at the forefront of the pain management landscape. Investors and industry observers will be closely monitoring the company's ability to translate this latest round of backing into long-term value creation and continued market penetration.
See full Collegium Pharmaceutical company page
